Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Immune Thrombocytopenic Purpura Clinical Trial

Official title:

Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00426270
• Other study ID #: GAM10-02
• Status: Completed
• Phase: Phase 3
• First received: January 22, 2007
• Last updated: July 28, 2014
• Start date: June 2006
• Est. completion date: September 2008

Study information

• Verified date: July 2014
• Source: Octapharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Paul-Ehrlich-InstitutCzech Republic: State Institute for Drug ControlAustria: Agency for Health and Food SafetyPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Octagam is a solvent/detergent-treated human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in about 80 countries. This study evaluated the efficacy and safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura (ITP) in adults. As Octagam 10% is essentially similar to Octagam 5%, it is expected that Octagam 10% is as efficacious and safe (in respect to viral safety) as Octagam 5%.

Description:

The primary objective of the study was to investigate the efficacy of Octagam® 10% in correcting platelet count. The blood count as well as laboratory chemistry were checked repeatedly up to day 21.

The secondary objective of the study was to investigate the safety of Octagam® 10%. Safety was assessed by monitoring vital signs, evaluating adverse events, assessing laboratory parameters, and by viral safety testing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) according to standard criteria.

• Platelet count = 20 x 10^9/L.

Key Exclusion Criteria:

• Chronic refractory ITP patients.

• Thrombocytopenia secondary to other diseases, or drug related thrombocytopenia.

• Administration of IGIV, anti-D, or other platelet enhancing drugs within 30 days before enrollment.

• Administration of thrombocyte concentrates within 72 hours before baseline.

• Experimental treatment (eg, rituximab) within 3 months before enrollment.

• Prophylactic preoperative treatment for elective splenectomy.

• Severe liver or kidney disease.

• Pregnant or nursing female.

• History of hypersensitivity to blood or plasma derived products.

• Emergency operation.

• Live viral vaccination within the last month prior to study entry.

• Known IgA deficiency and antibodies against IgA.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Immune Thrombocytopenic Purpura
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombocytopenic, Idiopathic

Intervention

Drug:
• Octagam 10%
Octagam 10% was supplied as a ready-to-use solution in glass bottles.

Locations

Country	Name	City	State
Austria	Contact Octapharma for information	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Octapharma

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With a Clinical Response	A clinical response is defined as an increase in platelet count to = 50*10^9/L on any day from Day 2 to Day 7.	Day 2 to Day 7	No
Secondary	Time to Achieve a Clinical Response	A clinical response is defined as an increase in platelet count to = 50*10^9/L on any day from Day 2 to Day 7.	Day 2 to Day 7	No
Secondary	Maximum Platelet Count	Platelet count was assessed on Days 2 through 7 and on Days 14, 21, and 63. The maximum measured platelet count is reported.	Day 2 to the end of the study (Day 63)	No
Secondary	Duration of the Clinical Response	The duration of the clinical response was the number of days that the platelet count remained = 50*10^9/L. Platelet count was assessed on Days 2 through 7 and on Days 14, 21, and 63. A conservative method was used to calculate the duration of the clinical response. For example, if the platelet count was = 50*10^9/L on Day 7 and dropped below 50*10^9/L at Day 14, Day 7 was used as the last day to calculate the duration of the clinical response. The same procedure was used if the platelet count dropped below 50*10^9/L at Day 21 from Day 14 or Day 63 from Day 21.	Day 2 to the end of the study (Day 63)	No
Secondary	Percentage of Participants With None, Minor, Mild, or Moderate Bleeding at Day 7	The investigator evaluated the severity of bleeding using the following rating scale: None (definitely no haemorrhage of any kind), Minor (few petechiae [= 100 total] and/or = 5 small bruises [= 3 cm diameter], no mucosal bleeding), Mild (many petechiae [> 100 total] and/or > 5 large bruises [> 3 cm diameter], no mucosal bleeding), Moderate (overt mucosal bleeding [epistaxis, gum bleeding, oropharyngeal blood blisters, menorrhagia, gastrointestinal bleeding, etc] that does not require immediate medical attention or intervention).	Day 7	No